Disease Modifying Trial Designs and Statistical Analysis
*Chunming M. Li, Pfizer 

Keywords:

Disease modifying drugs development is certainly one of the most challenging areas in terms of design, analysis and registration. In many disease areas (Osteoarthritis and Alzheimer’s disease, for example), such a success would mean great market potential. The roundtable will focus on previous experience, FDA perspective and biomarker applications. Please feel free to bring your case study for group discussion.